Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 18/20 | 0.61 |
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578958 | 0.87 | CCR3 (0.59) | CCR3HTR2A | |
| SCHEMBL4577435 | 0.85 | CCR3 (0.66) | CCR3HTR2A | |
| SCHEMBL4576687 | 0.81 | CCR3 (0.71) | CCR3HTR2A | |
| SCHEMBL7829233 | 0.80 | CCR3 (0.73) | CCR3HTR2A | |
| SCHEMBL6215479 | 0.78 | CCR3 (0.75) | CCR3HTR2A | |
| SCHEMBL4579363 | 0.78 | GRIN2B (0.53) | CCR3 | |
| SCHEMBL27590237 | 0.77 | GRIN1 (0.52) | CCR3 | |
| SCHEMBL6338760 | 0.76 | CCR3 (1.00) | CCR3HTR2A | |
| SCHEMBL7825964 | 0.76 | CCR3 (0.75) | CCR3HTR2A | |
| Hydrochloric Acid SCHEMBL4578835 | 0.76 | CCR3 (0.46) | CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| CN-100413860-C | piperidine derivatives as NMDA receptor antagonists | HUNGARY GIREL GYOGYSZERGYAR (HU) | 2008-08-27 | — | — | CN | disclosed |
| CN-1556805-A | piperidine derivatives as NMDA receptor antagonists | ������ҩ������˾ | 2004-12-22 | — | — | CN | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | CCR3 672/4885HTR2A 342/4885MGLL 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.